The firm keeps a Neutral rating on the shares ahead of the highly anticipated binary Maritide readout end-Q3. TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers.

Let me address MariTide directly. Our ongoing Phase 2 study is progressing well, and we look forward to sharing results later this year. We're well advanced in preparing to launch a broad Phase 3 ...

Amgen Inc (NASDAQ:AMGN) is advancing its pipeline with potentially first-in-class or best-in-class medicines, including MariTide for obesity and type 2 diabetes. The rare disease portfolio delivered ...

Let me address MariTide directly. Our ongoing Phase II study is progressing well, and we look forward to sharing results later this year. We're well advanced in preparing to launch a broad Phase ...

In the pipeline, Amgen’s obesity drug candidate MariTide remains the most important potential growth driver. We assume $8.5 billion in sales by 2033 (at a 60% probability of approval ...

Amgen Inc (NASDAQ:AMGN) is advancing its pipeline with potentially first-in-class or best-in-class medicines, including MariTide for obesity and type 2 diabetes. The rare disease portfolio ...

Amgen released its third-quarter earnings report on Wednesday, revealing an overall solid performance in Q3 despite misses by some of its key products. The company’s revenues in the quarter came in at ...

"We're well advanced in preparing to launch a broad Phase 3 program for MariTide including obesity, obesity-related conditions and type 2 diabetes," Amgen CEO Bob Bradway said on a conference call.

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects ...

Most of the Oct. 30 investor call revolved around MariTide, Amgen’s clinical-stage obesity candidate. On the call, the Big Pharma disclosed the launch of a phase 2 study assessing MariTide in ...